A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Research highlights media misrepresentation of COVID-19 drug efficacy. ... For the study, the researchers conducted an analysis of 479 reports of hydroxychloroquine, ...

Ahead of a U.S Food and Drug Administration advisory panel meeting, drugmaker Merck has revealed final analysis data from a Phase 3 trial testing its oral antiviral pill against COVID-19.

Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its ...

However, the efficacy estimates of the COVID-19 vaccines from the trials mentioned above were much higher than the FDA and WHO threshold. In all the different trials, different factors have been ...

Additional efficacy assessments were the prevention of severe or moderate-to-severe Covid-19 (a post hoc analysis), viral load at diagnosis, and variant-specific efficacy.

Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously ...

With the results, the pharmaceutical giant pulls ahead of other companies developing injectable versions of antibody drugs for Covid-19 prevention. By Frank Vinluan on August 20, 2021 4:42 pm.

AstraZeneca said its latest figure on the vaccine’s efficacy was based on an analysis of 190 cases of symptomatic Covid-19 in the trial, 49 more cases than the company had analyzed earlier ...

The Food and Drug Administration released an analysis of Johnson & Johnson's COVID-19 vaccine Wednesday morning that appears to support its authorization for emergency use.